22 May 2013
Keywords: strong, ph, ii, data, genzyme/bayer, ms, drug
Article | 14 May 2007
US biotechnology major Genzyme and German drugmaker Bayer Healthcare reported positive interim data from the CAMMS223 Phase II study of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
7 May 2007
14 May 2007
© 2013 thepharmaletter.com